Searchable abstracts of presentations at key conferences in endocrinology

ea0022p816 | Thyroid | ECE2010

A single small dose of rituximab may be effective in Graves' orbitopathy

Covelli Danila , Vannucchi Guia , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

The anti-CD 20 antibody rituximab (RTX) has been employed in the treatment of several autoimmune diseases and its effect may not involve autoantibody secretion. Preliminary studies have shown that RTX induced improvement of active Graves’ orbitopathy (GO) but caused no change of serum anti-thyroid antibodies in relation to peripheral CD 20+ cells depletion, usually observed at the second week after therapy. A 50-year-old woman with GO predominantly active in the left eye ...

ea0020p120 | Thyroid | ECE2009

Seasonal occurrence of Graves’ disease and associated orbitopathy at diagnosis

Campi Irene , Vannucchi Guia , Covelli Danila , Curro Nicola , Dazzi Davide , Beck-Peccoz Paolo , Salvi Mario

A seasonal occurrence of Graves’ disease (GD) has been reported in previous studies, with a peak of frequency in the warmer half of the year (Ford 1988, 1991, Westphal 1994) or the period of the year with a higher iodine intake (Phillips 1985); other studies (Facciani 2000) have failed to find a different seasonal occurrence of Graves’ orbitopathy (GO). Aim of the present study was to evaluate a possible seasonal difference in the onset of GD and GO in a series of ou...

ea0016p764 | Thyroid | ECE2008

Clinical features and outcome of papillary thyroid cancers <2 cm: univariate and multivariate analyses

Perrino Michela , Vannucchi Guia , Vicentini Leonardo , Dazzi Davide , Peccoz Paolo Beck

An increasing prevalence of papillary thyroid carcinomas (PTC) of small size have been recorded in recent years. These tumors have a favorable outcome in most cases, and total thyroidectomy without radioiodine therapy is suggested for microcarcinomas (defined as ≤1 cm). The 6th edition of the TNM staging system for thyroid cancers includes in the T1 category tumors ≤2 cm, limited to the thyroid. Aim of the present study was to evaluate the clinical/pathological fea...

ea0037gp.27.05 | Thyroid – hyperthyroidism and treatment | ECE2015

Effect of a very low dose of rituximab on active moderate–severe Graves' orbitopathy: an interim report

Vannucchi Guia , Campi Irene , Covelli Danila , Curro Nicola , Dazzi Davide , Avignone Sabrina , Sina Clara , Guastella Claudio , Pignataro Lorenzo , Salvi Mario

Previous studies have shown that Rituximab (RTX) is effective as a disease modifying drug at doses of 500 mg or 1000×2 mg in active Graves’ orbitopathy (GO). We have conducted a pilot study (EUDRACT 2012-001980-53) in which patients with active moderate-severe GO were treated with a single infusion of low dose RTX (100 mg). Ten patients were enrolled of whom seven completed the study at 52 weeks. Five patients did not respond to a previous treatment with i.v. methylp...

ea0016p765 | Thyroid | ECE2008

A prospective study on a large series of non toxic multinodular goiters treated with radioiodine: results at long term follow-up

Vannucchi Guia , Mannavola Deborah , Chiti Arturo , Dazzi Davide , Rodari Marcello , Tadayyon Sara , Beck-Peccoz Paolo , Fugazzola Laura

Radioiodine (131I) administration has been found to be effective in the treatment of hyperfunctioning and normofunctioning multinodular goiter. Moreover, lithium therapy has been shown to enhance the radioiodine efficacy and to reduce the transient thyrotoxicosis induced by radioiodine.Aim of the present study was to evaluate the long term efficacy of 131I with or without lithium administration in the treatment of non toxic multinod...

ea0016p810 | Thyroid | ECE2008

Effects of rituximab (RTX) treatment on IL-6 and soluble IL-6 receptor secretion in patients with thyroid-associated ophthalmopathy (TAO)

Campi Irene , Vannucchi Guia , Dazzi Davide , Covelli Danila , Bonara Paola , Curro Nicola , Beck-Peccoz Paolo , Salvi Mario

We described a significant clinical response to RTX treatment in patients with active TAO. In order to understand the possible mechanisms of action of RTX, we measured serum concentrations of IL-6 and its soluble receptor (sIL-6R). We treated 10 patients with RTX: 8 women, 2 men aged 31–51 yr with Graves’ disease. We also treated 14 patients with i.v. steroids (IVGC). All had active TAO. In all patients we studied thyroid function, serum autoantibodies and peripheral...

ea0081rc11.1 | Rapid Communications 11: Thyroid 2 | ECE2022

Impact of Covid-19 disease on thyroid function: longitudinal study

Muller Ilaria , Varallo Matteo , Daturi Anita , E Re Tiziana , Dazzi Davide , Longari Virgilio , Gori Andrea , Mantovani Giovanna , Arosio Maura , Salvi Mario

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic disease (Covid-19) affects thyroid function with different mechanisms: non-thyroidal illness syndrome (NTIS), direct infection of thyroid gland and cytokine storm. We provided the first description of painless atypical thyroiditis coexisting with NTIS in patients hospitalised for moderate-to-severe Covid-19 disease. We aimed to: 1) correlate thyroid dysfunction with Covid-19 disease severity;...

ea0037gp.07.01 | Reproduction: Female and other | ECE2015

Preconceptional TSH and miscarriage in infertile women submitted to IVF

Vannucchi Guia , Covelli Danila , Renzini Mario , Brigante Claudio , Coticchio Giovanni , Canto Maria Beatrice Dal , Fadini Rubens , Dazzi Davide , Negro Roberto , Fugazzola Laura

It is known that high levels of TSH are associated with higher miscarriage risk, though the precise TSH cut-offs are debated. Aim of the present study was to evaluate if pre-conceptional TSH levels associate with increased risk of early miscarriage in a large series of infertile women submitted to IVF and to determine the threshold of TSH associated with the highest prevalence of pregnancy loss. We retrospectively studied 1484 infertile women (mean±age 36.7±4.1 years...

ea0070yi9 | Young Investigators | ECE2020

Comparison between the efficacy of the Anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves’ orbitopathy: an interim analysis

lazzaroni Elisa , Covelli Danila , Currò Nicola , Campi Irene , Vannucchi Guia , Dazzi Davide , Muller Ilaria , Guastella Claudio , Dolci Alessia , Arosio Maura , Salvi Mario

Background: BAFF is a Serum B cell stimulating factor shown elevated in Graves’ disease, compared to controls (Vannucchi 2012). BAFF and its receptor are expressed on lymphocytes infiltrating the thyroid in Graves’ disease as well as on thyrocytes themselves (Campi 2015).Aims: A single-blind randomized controlled trial (EudraCT 2015-002127-26) has been conducted to test the efficacy of the anti-BAFF monoclonal antibody belimumab (BMB) in acti...

ea0020p68 | Thyroid | ECE2009

Treatment of patients with Graves’ orbitopathy (GO) with rituximab: effects on humoral immunity

Vannucchi Guia , Campi Irene , Bonomi Marco , Curro Nicola , Dazzi Davide , Covelli Danila , Bonara Paola , Persani Luca , Wall Jack , Beck-Peccoz Paolo , Salvi Mario

Rituximab (RTX) is a monoclonal antibody which binds CD20 antigen and induces B cell depletion. It is not known if its therapeutic effect in autoimmune diseases is mediated by modifications of the humoral immune response, namely the antibody production. Aim of the present study was to evaluate the effect of RTX on serum TSH-receptor antibodies, both binding (TBII) and stimulating (TSAb) and on serum antibodies against three orbital antigens, calsequestrin, XIII collagen and th...